Price
$2.43
Increased by +1.67%
Dollar Volume
2.24 M
ADR%
4.75
Earnings Report Date (estimate)
Feb 28, 23 (0.21)
Market Cap.
737.73 M
Shares Float
101.25 M
Shares Outstanding
151.48 M
Beta
1.35
Price / Earnings
243.00
BPR
108.42
20D Range
2.05 2.46
50D Range
1.96 2.65
200D Range
1.95 4.25
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 4, 22 0.14
Decreased by -22.22%
0.18
Decreased by -22.22%
Aug 5, 22 0.19
Decreased by -9.52%
0.19
May 4, 22 0.12
Decreased by -52.00%
0.13
Decreased by -7.69%
Mar 2, 22 0.18
Decreased by -10.00%
0.20
Decreased by -10.00%
Mar 1, 22 0.18
Increased by +28.57%
0.20
Decreased by -10.00%
Nov 3, 21 0.21
Increased by +31.25%
0.20
Increased by +5.00%
Aug 9, 21 0.25
Increased by +92.31%
0.18
Increased by +38.89%
May 7, 21 0.20
Increased by 0.00%
0.18
Increased by +11.11%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 545.56 M
Increased by +3.21%
-2.69 M
Increased by +36.54%
Decreased by -0.49%
Increased by +38.51%
Jun 30, 22 559.36 M
Increased by +4.54%
-120.81 M
Decreased by -931.32%
Decreased by -21.60%
Decreased by -895.24%
Mar 31, 22 497.63 M
Increased by +0.92%
-2.16 M
Decreased by -132.15%
Decreased by -0.43%
Decreased by -131.86%
Dec 31, 21 536.90 M
Increased by +5.27%
-6.38 M
Decreased by -109.98%
Decreased by -1.19%
Decreased by -99.47%
Sep 30, 21 528.59 M
Increased by +1.79%
-4.24 M
Increased by +52.79%
Decreased by -0.80%
Increased by +53.62%
Jun 30, 21 535.08 M
Increased by +15.15%
14.53 M
Increased by +221.14%
Increased by +2.72%
Increased by +205.20%
Mar 31, 21 493.11 M
Decreased by -1.09%
6.71 M
Decreased by -94.17%
Increased by +1.36%
Decreased by -94.11%
Dec 31, 20 510.03 M
Increased by +28.37%
-3.04 M
Increased by +90.55%
Decreased by -0.60%
Increased by +92.64%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.